A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer.
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2018
At a glance
- Drugs DPX 0907 (Primary)
- Indications Breast cancer; Ovarian cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors IMV
- 03 May 2018 According to an IMV media release, Immunovaccine has changed its name to IMV.
- 06 Aug 2012 Results were published in the Journal of Translational Medicine, according to an Immunovaccine media release. Results were also reported in the media release.
- 04 Jun 2012 Results have been presented at ASCO-2012 according to an Immunovaccine media release. Results were also summarised in the media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History